Zuerich, Switzerland

Alexandre Passioukov


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Alexandre Passioukov in Cancer Treatment

Introduction

Alexandre Passioukov is a notable inventor based in Zurich, Switzerland. He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on enhancing the efficacy of anti-cancer therapies, particularly through the use of antibodies.

Latest Patents

One of Alexandre Passioukov's key patents is titled "Predictive biomarker for cancer treatment with ADCC-enhanced antibodies." This invention is directed towards methods for identifying which patients diagnosed with cancer will most benefit from treatment using an anti-cancer therapy that comprises an ADCC-enhanced antibody. This advancement has the potential to improve patient outcomes by personalizing cancer treatment.

Career Highlights

Alexandre Passioukov is currently associated with Roche Glycart AG, a leading company in the biopharmaceutical sector. His role at Roche Glycart AG allows him to work on cutting-edge research that aims to revolutionize cancer therapies. His expertise and innovative mindset have positioned him as a valuable asset in the field of oncology.

Collaborations

Alexandre collaborates with talented professionals in his field, including Lilla Di Scala and Stefan Evers. These collaborations enhance the research environment and contribute to the development of groundbreaking cancer treatment solutions.

Conclusion

In summary, Alexandre Passioukov is a prominent inventor whose work in cancer treatment is paving the way for more effective therapies. His patent on predictive biomarkers showcases his commitment to improving patient care in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…